Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 14;11(12):202. doi: 10.1038/s41408-021-00594-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Unsupervised clustering of 83 hematological patients and 102 health care practitioners (HCPs) based on the relative percentile distribution of 59 immune cell types in peripheral blood before vaccination, categorized into four groups: granulocytes, antigen-presenting cell (APC) subsets, T-cell and B-cell subsets. For the columns to the left of the cell-percentage data, moving from left to right, rows are color-coded according to gender, age groups, type and subtype of hematological malignancy, treatment status, number of previous lines of therapy, immunoparesis, autologous transplant, treatment with anti-CD20 antibodies, anti-CD38 antibodies and immunomodulatory drugs (IMiDs), depth of response to treatment (complete remission, CR), previous SARS-CoV-2 infection, and vaccine type. For the columns to the right of the cell-percentage data, moving from left to right, rows are color-coded according to seroconversion and presence of ≥553.5 IU/mL IgG against the receptor-binding domain (RBD) of the S-glycoprotein. CM, central memory; EM, effector memory; Treg, T regulatory cells; Tfh, T follicular-like; TEMRA, terminally effector memory CD45RA+; PC, plasma cells.